Anti-nucleosome antibodies are autoantibodies that target nucleosomes (DNA-histone complexes). They are primarily associated with systemic lupus erythematosus (SLE) and drug-induced lupus.
Nucleosomen Antikörper is often considered in the context of tiredness, reduced capacity, brain fog, or chronic exhaustion. This short overview clarifies what the marker can contribute, where its limits are, and when symptom or illness context becomes more important.
Nucleosomen Antikörper becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
Nucleosomen Antikörper does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
Anti-nucleosome antibodies are autoantibodies that attack nucleosomes, structures consisting of DNA wound around histone proteins. They are a subset of antinuclear antibodies (ANA) and are considered highly sensitive for systemic lupus erythematosus (SLE), particularly during active disease. These antibodies can also appear in drug-induced lupus and, less commonly, in other autoimmune conditions.
Measuring anti-nucleosome antibodies, usually by enzyme-linked immunosorbent assay (ELISA), helps clinicians evaluate suspected SLE or monitor disease activity. A positive result can support a diagnosis when clinical symptoms are present, though it is not used in isolation.
A value below the lab-specific cutoff (often <20 U/mL, lab-dependent) is considered negative and typically indicates no significant anti-nucleosome antibody level. This may suggest the absence of SLE or other autoimmune conditions associated with these antibodies. However, a negative result does not entirely rule out SLE, especially in early or treated disease, as antibody levels can fluctuate.
A value above the lab-specific cutoff (e.g., ≥20 U/mL, lab-dependent) is considered positive. Elevated anti-nucleosome antibodies are strongly associated with SLE, particularly with active disease and renal involvement (lupus nephritis). They may also be found in drug-induced lupus. Higher titers often correlate with disease activity, but the result must be interpreted alongside clinical findings and other laboratory tests.
This result is not specific for ME/CFS or Long COVID. Read it together with the clinical question, symptoms, related findings and the laboratory reference range rather than in isolation.
Practical details are separated from the general FAQ so they are easier to find.
The test is performed on a blood sample using an ELISA method. It specifically detects antibodies that target nucleosomes, differentiating them from other antinuclear antibodies. Results usually take a few days to come back.
Nucleosomen Antikörper becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
You now know which questions can matter when reading this result. With Elara you can keep the value and its surrounding context together over time.
Save the lab value with its date so individual measurements do not get lost.
See previous measurements together instead of relying on a single snapshot.
View Anti-Nucleosome Antibodies alongside symptom, energy, sleep and PEM entries without assuming one caused the other.
Export your history as a PDF — structured for the next check-up.
Normal, or negative, is typically defined as less than 20 U/mL, but this cutoff depends on the laboratory and testing method. Results are reported as positive or negative, and values above the threshold suggest the presence of the antibodies.
A high, positive level often points to systemic lupus erythematosus (SLE), especially when the disease is active or involves the kidneys. It can also occur in drug-induced lupus and, on occasion, in other autoimmune disorders. Clinical context is essential for interpretation.
Yes. A negative result does not exclude SLE. Antibody levels can vary over time, and some patients may produce other autoantibodies instead. Diagnosis relies on a combination of symptoms, physical examination, and multiple lab tests.
Nucleosomen Antikörper does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
For many fatigue-related, inflammatory, hormonal, or recovery-linked markers, interpretation becomes stronger when symptoms, exertion response, and daily function are considered together.
Nucleosomen Antikörper is rarely meaningful in isolation when fatigue, brain fog, or unstable capacity are central. The fatigue hub provides the broader lab-and-symptom context.
If symptoms worsen after activity with a delay, PEM often explains more than an isolated lab value alone.
Questionnaires help connect biomarkers to symptom patterns, functional limits, and patient-reported change over time.
Markers from the same system can add useful context when a single lab value is hard to interpret on its own.
No individual medical review is documented.
This English content was created with AI assistance and automatically validated. This is not an individual medical review.
This information does not replace medical advice. Lab values should be assessed in the context of your medical history, the reason for testing and other findings. Elara provides health information for orientation — not diagnoses or treatment decisions.
Bring your lab values, symptoms and energy into one shared context — so you walk into your next appointment more informed and structured.
